Phase 1 Clinical Trial Results Using Satipharm Capsules Published in International Medical Journal

Phase 1 Clinical Trial Results Using Satipharm Capsules Published in
International Medical Journal

VANCOUVER, British Columbia,  Nov. 16,  2017 (GLOBE NEWSWIRE)  -- Harvest  One 
Cannabis Inc.  (TSX-V:HVST) ("Harvest  One") through  its wholly  owned  Swiss 
Subsidiary Satipharm AG ("Satipharm") is  pleased to advise that results  from 
the Phase 1  Clinical Trial  undertaken by PhytoTech  Therapeutics ("PTL")  in 
Israel using Satipharm’s proprietary GelpellR technology have been published.

The  article  “Single-Dose  Pharmacokinetics  of  Oral  Cannabidiol  Following 
Administration of PTL101: A  New Formulation Based  on Gelatin Matrix  Pellets 
Technology” has been  published in Clinical  Pharmacology in Drug  Development 
(“CPDD”). 

The PTL101  drug beads  utilise a  proprietary formulation  developed  through 
Satipharm’s  Gelpell-CBD™  product   technology,  which  contain   organically 
derived, highly purified CBD.

Established in 2012, CPDD is  an international, peer-reviewed publication  and 
the official  journal  of  the  American  College  of  Clinical  Pharmacology, 
providing a forum  for the  presentation of  first-time-in-man study  results. 
CPDD publishes high-quality clinical pharmacology studies in drug  development 
which are  primarily  (but not  exclusively)  performed in  early  development 
phases in healthy subjects. 

PTL completed its Phase 1 Clinical Trial of the PTL101 capsules in March 2016,
with results demonstrating the safety and high performance of the oral capsule
technology, including the  effective delivery profile  of cannabidiol  (“CBD”) 
compound to trial subjects.

The Phase 1 Clinical Trial also highlighted the favourable bioavailability  of 
the capsules  in  comparison  to  Sativex  –  a  market-leading,  commercially 
available cannabinoid oral spray produced by GW Pharmaceuticals.

Phase 2 Clinical Trial Update

PTL has since commenced its  Phase 2 Clinical Trial  into the efficacy of  the 
PTL101 capsules in treating refractory epilepsy in children.

The completion  of this  Phase 2  Clinical  Trial would  be a  major  catalyst 
towards  the  commercial  development  of   the  PTL101  capsules,  with   PTL 
potentially only  the  third  company  behind  GW  Pharmaceuticals  and  Insys 
Therapeutics Inc. to present results of  a formal Phase 2 Clinical Trial  into 
refractory epilepsy in children.

In addition, a Phase 2 Clinical Trial  into the safety and efficacy of  PTL201 
capsules in treating spasticity related symptoms of multiple sclerosis  (“MS”) 
patients is planned to commence in due course.

About Harvest One

Harvest One Cannabis Inc. (TSXV:  HVST) controls operations across the  entire 
cannabis value chain through three business units, with Harvest One serving as
the umbrella company over horticultural arm United Greeneries and medical  arm 
Satipharm  AG.   Each  business   is  strategically   located  in   favourable 
jurisdictions  with  supportive   regulatory  frameworks   in  place.   United 
Greeneries has received  a Canadian medicinal  cannabis cultivation and  sales 
license, making Harvest  One one  of only a  few companies  globally with  the 
capacity to commercially cultivate and sell cannabis in a federally  regulated 
environment.

For more information on Harvest One Cannabis, please contact:

Colin Clancy
Investor Relations
+ 1 (877) 915 7934
cclancy@mmj.ca

Certain statements contained in this press release constitute  forward-looking 
information. These statements relate to  future events or future  performance. 
The use of any  of the words "could",  "intend", "expect", "believe",  "will", 
"projected", "estimated" and  similar expressions and  statements relating  to 
matters that are not historical facts are intended to identify forward-looking
information and are based on the Company's current belief or assumptions as to
the outcome and timing of such future events. Actual future results may differ
materially. The forward-looking information contained in this press release is
made as of  the date  hereof and  the Company is  not obligated  to update  or 
revise  any  forward-looking   information,  whether  as   a  result  of   new 
information, future  events or  otherwise, except  as required  by  applicable 
securities laws. Because of the risks, uncertainties and assumptions contained
herein,  investors  should  not   place  undue  reliance  on   forward-looking 
information. The foregoing  statements expressly  qualify any  forward-looking 
information contained herein.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accept
responsibility for the adequacy or accuracy of this release.
Press spacebar to pause and continue. Press esc to stop.